|
Results of a phase II multicenter study of obinutuzumab plus bendamustine in pts with previously untreated chronic lymphocytic leukemia (CLL). |
|
|
|
Consulting or Advisory Role - Celgene; Genentech; Gilead Sciences; Pharmacyclics; TG Therapeutics |
Speakers' Bureau - Gilead Sciences |
Research Funding - Acerta Pharma (Inst); Celgene (Inst); Genentech (Inst); Gilead Sciences (Inst); Merck (Inst); Pharmacyclics (Inst); Seagen (Inst); Takeda (Inst); TG Therapeutics (Inst) |
Expert Testimony - Gilead Sciences |
|
|
No Relationships to Disclose |
|
|
Stock and Other Ownership Interests - AstraZeneca; Johnson & Johnson; Merck; Novartis |
Speakers' Bureau - Incyte |
|
|
No Relationships to Disclose |
|
|
Employment - Fort Wayne Medical Oncology & Hematology |
Stock and Other Ownership Interests - Fort Wayne Medical Oncology & Hematology |
Honoraria - Abbvie; Alexion Pharmaceuticals; Bristol-Myers Squibb |
Consulting or Advisory Role - Abbvie; Alexion Pharmaceuticals; Bristol-Myers Squibb |
Speakers' Bureau - Alexion Pharmaceuticals |
Research Funding - Alexion Pharmaceuticals (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Janssen (Inst); Lilly (Inst); Medivation (Inst); Novartis (Inst); Roche (Inst); Syndax (Inst); TG Therapeutics (Inst) |
Travel, Accommodations, Expenses - Abbvie; Alexion Pharmaceuticals; Bristol-Myers Squibb |
|
|
|
Stock and Other Ownership Interests - Genentech |
Research Funding - Genentech |
Travel, Accommodations, Expenses - Genentech |
|
|
|
Stock and Other Ownership Interests - Genentech |
Other Relationship - Genentech |
|
|
Employment - Genentech/Roche |
Stock and Other Ownership Interests - Genentech/Roche |
|
Alexey Valeryevich Danilov |
Honoraria - Dava Oncology |
Consulting or Advisory Role - Pharmacyclics; Piramal Life Science |
Research Funding - AstraZeneca; Piramal Life Science; Takeda |